RenovoRx

company

About

RenovoRx is developing innovative solutions for targeted delivery of fluids to selected sites in the peripheral vascular system.

  • 1 - 10

Details

Last Funding Type
Series D
Last Funding Money Raised
$8.30M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market.

RenovoRx has a motivated Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of interventional radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$8.30M
RenovoRx has raised a total of $8.30M in funding over 2 rounds. Their latest funding was raised on Jun 19, 2018 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 19, 2018 Series D $8.30M 1 Boston Scientific Detail
Dec 7, 2015 Series C 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
RenovoRx is funded by 2 investors. Boston Scientific and Next Wave/Portfolia Angel Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Boston Scientific Yes Series D
Next Wave/Portfolia Angel Fund Series C